TY  - JOUR
AU  - Gross-Goupil, Marine
AU  - Ravaud, Alain
PY  - 2012
TI  - Tivozanib: is total VEGFR inhibition the way to success in terms of tolerability and efficacy in advanced kidney cancer?
JF  - Translational Andrology and Urology; Vol 1, No 3 (September 17, 2012): Translational Andrology and Urology
Y2  - 2012
KW  - 
N2  - The fami ly of t yrosine k inase inhibitors is st i l l growing. After sunitinib, sorafenib and more recently pazopanib, and axitinib, we probably now should count on tivozanib (1). This pan-VEGFR inhibitor (VEGFR1,- R2,-R3) is more selective and potent in vitro than previous known TK inhibitors. Tivozanib was tested in a phase II trial reported by Nosov et al. (1) Tivozanib was administered at a daily dose of 1.5 mg, for 3 weeks followed by a break of 1 week. Of the 272 patients treated during the first period of 16 weeks, 78, who presented tumour shrinkage of at least 25%, were maintained on tivozanib. All of the 118 patients who presented less than 25% change in the tumour, were randomized between placebo and tivozanib, during the next 12 weeks.
UR  - https://tau.amegroups.org/article/view/1065